MX2021005463A - Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). - Google Patents

Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).

Info

Publication number
MX2021005463A
MX2021005463A MX2021005463A MX2021005463A MX2021005463A MX 2021005463 A MX2021005463 A MX 2021005463A MX 2021005463 A MX2021005463 A MX 2021005463A MX 2021005463 A MX2021005463 A MX 2021005463A MX 2021005463 A MX2021005463 A MX 2021005463A
Authority
MX
Mexico
Prior art keywords
mcl
spiro
inhibitors
protein
cell leukemia
Prior art date
Application number
MX2021005463A
Other languages
English (en)
Inventor
Jincong Zhuo
Juan Luengo
Rupa Shetty
Raul Leal
Andrew Paul Combs
Peng Wei
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MX2021005463A publication Critical patent/MX2021005463A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La divulgación se refiere a compuestos de la Fórmula I (ver Fórmula) También se describen composiciones farmacéuticas que comprenden compuestos de la Fórmula I, así como métodos para su uso y preparación.
MX2021005463A 2018-11-09 2019-11-08 Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). MX2021005463A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862758202P 2018-11-09 2018-11-09
US201962907451P 2019-09-27 2019-09-27
US201962909635P 2019-10-02 2019-10-02
PCT/US2019/060638 WO2020097577A1 (en) 2018-11-09 2019-11-08 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein

Publications (1)

Publication Number Publication Date
MX2021005463A true MX2021005463A (es) 2021-06-18

Family

ID=68808529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005463A MX2021005463A (es) 2018-11-09 2019-11-08 Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).

Country Status (12)

Country Link
US (2) US11130769B2 (es)
EP (1) EP3877390A1 (es)
JP (1) JP2022506973A (es)
KR (1) KR20210089662A (es)
CN (1) CN113166173A (es)
AU (1) AU2019374907A1 (es)
BR (1) BR112021008796A2 (es)
CA (1) CA3118919A1 (es)
IL (1) IL283078A (es)
MA (1) MA54157A (es)
MX (1) MX2021005463A (es)
WO (1) WO2020097577A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3793565T3 (pl) 2018-05-14 2022-05-02 Gilead Sciences, Inc. Inhibitory MCL-1
AU2020309745A1 (en) 2019-07-09 2022-03-03 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as MCL-1 inhibitors
EP4013762A1 (en) * 2019-08-16 2022-06-22 Inflazome Limited Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
US20220289766A1 (en) * 2019-08-16 2022-09-15 Inflazome Limited Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
JP7441947B2 (ja) 2019-11-26 2024-03-01 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ１阻害剤を調製するためのプロセス及び中間体
KR20230024287A (ko) * 2020-05-13 2023-02-20 프렐루드 테라퓨틱스, 인코포레이티드 골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서의 스피로-술폰아미드 유도체
JP2023528965A (ja) * 2020-06-10 2023-07-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としての大環状２－アミノ－３－フルオロ－ブタ－３－エナミド
AU2021404501A1 (en) 2020-12-17 2023-08-03 Janssen Pharmaceutica Nv Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
CA3215312A1 (en) 2021-04-26 2022-11-03 Frederik Jan Rita Rombouts Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
TW202315637A (zh) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
TW202317200A (zh) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Ｍｃｌ－１抑制劑與抗體藥物接合物之組合
CN115677616B (zh) * 2021-11-03 2024-10-18 中国药科大学 大环磺酰胺类化合物及其制备方法和医药用途
CA3237011A1 (en) 2021-11-16 2023-05-25 Soufyan JERHAOUI Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
ME03780B (me) * 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
JO3474B1 (ar) * 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
CN106565706B (zh) * 2016-10-27 2018-05-01 广东东阳光药业有限公司 一种磺酰胺衍生物及其在药学中的应用
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物

Also Published As

Publication number Publication date
US11130769B2 (en) 2021-09-28
US20200148705A1 (en) 2020-05-14
WO2020097577A1 (en) 2020-05-14
JP2022506973A (ja) 2022-01-17
KR20210089662A (ko) 2021-07-16
CA3118919A1 (en) 2020-05-14
MA54157A (fr) 2021-09-15
IL283078A (en) 2021-06-30
AU2019374907A1 (en) 2021-06-03
BR112021008796A2 (pt) 2021-08-03
CN113166173A (zh) 2021-07-23
EP3877390A1 (en) 2021-09-15
US20230010358A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
NZ769257A (en) Mcl-1 inhibitors
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
SA520420033B1 (ar) مركبات صيدلية
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
EA202090419A1 (ru) Селективные ингибиторы инфламмасомы nlrp3
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EP4371562A3 (en) 2-quinolone derived inhibitors of bcl6
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
MX2023003264A (es) Inhibidores de cdk y su uso como productos fármaceuticos.
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors